(NP (NP (NN Enhancing) (NN effect)) (PP (IN of) (NP (CD 17) (NN beta-estradiol))) (PP (IN on) (NP (JJ human) (NN NK) (NN cell) (NN activity))) (. .))
(S (NP-SBJ-28 (NP (DT The) (ADJP (FW in) (FW vitro)) (NN effect)) (PP (IN of) (NP (CD 17) (NN beta-estradiol))) (PP (IN on) (NP (NN NK) (NN activity)))) (VP (VBD was) (VP (VBN studied) (NP (-NONE- *-28)))) (. .))
(S-COOD (S (NP-SBJ-29 (NP (DT The) (NP-COOD (NP (NN proliferation)) (CC and) (NP (NN NK) (NN activity)))) (PP (IN of) (NP (NP (NN YT-N17)) (PRN (-LRB- -LRB-) (NP (DT a) (JJ human) (JJ NK-like) (NN cell) (NN line)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN enhanced) (NP (-NONE- *-29)) (PP (IN by) (NP-LGS (NP (CD 17) (NN beta-estradiol)) (PRN (-LRB- -LRB-) (NP (NN E2)) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP-SBJ-30 (DT the) (NN enhancement)) (VP (VBD was) (VP (VBN blocked) (NP (-NONE- *-30)) (PP (IN by) (NP-LGS (NP (NP (NN tamoxifen)) (PRN (-LRB- -LRB-) (NP (NN Tx)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN antagonist)) (PP (IN of) (NP (NN E2))))))))) (. .))
(S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (NP-SBJ (NP (JJ other) (NN steroid) (NNS hormones)) (PP (JJ such) (IN as) (NP-COOD (NP (NN Tx)) (, ,) (NP (NN progesterone)) (, ,) (CC and) (NP (NN testosterone))))) (VP (VBD had) (NP (DT no) (NN effect))) (. .))
(S (NP-SBJ (NN YT-N17)) (VP (VBD contained) (NP (NP (NP (NP (ADJP (CD 11.8) (NN (mg fmol))) (NN protein)) (PP (IN of) (NP (NN estrogen) (NN receptor)))) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (PP (IN of) (NP (CD two) (JJ independent) (NNS assays)))) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN value)) (SBAR (WHNP-31 (WDT which)) (S (NP-SBJ (-NONE- *T*-31)) (VP (VBD was) (ADJP-PRD (ADJP (RB 5-10-fold) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (JJ other) (JJ hematopoietic) (NN cell) (NNS lines)))))))))))) (. .))
(S-COOD (S (NP-SBJ-32 (NP (DT An) (NN enhancement)) (PP (IN of) (NP (NN NK) (NN activity))) (PP (IN by) (NP (NN E2)))) (VP (VBD was) (VP (ADVP (RB also)) (VBN seen) (NP (-NONE- *-32)) (PP (IN in) (NP (NP (JJ large) (JJ granular) (NNS lymphocytes)) (VP (VBN obtained) (NP (-NONE- *)) (PP (IN from) (NP (JJ normal) (NNS subjects))))))))) (, ,) (CC and) (S (NP-SBJ-33 (PRP it)) (VP (VBD was) (VP (ADVP-TMP (RB again)) (VBN suppressed) (NP (-NONE- *-33)) (PP (IN by) (NP-LGS (NN Tx)))))) (. .))
(S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN E2)) (VP (VBZ is) (NP-PRD (NP (CD one)) (PP (IN of) (NP (NP (DT the) (VBG activating) (NNS factors)) (PP (IN for) (NP (NN (LGL NK)) (NNS cells)))))))))) (. .))
